TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
An announcement from MEDIROM Healthcare Technologies ( (MRM) ) is now available.
On October 20, 2025, MEDIROM Healthcare Technologies Inc. announced its Key Performance Indicators (KPIs) for September 2025, highlighting an increase in operational efficiency and customer engagement. The company served 72,236 customers with a sales per customer of ¥7,498, significantly above the industry average, and maintained a customer repeat ratio of 76.9%. Additionally, the company has expanded its health tech business, with its Lav® app reaching over 11,000 users, reflecting a growing market for health guidance services in Japan.
The most recent analyst rating on (MRM) stock is a Hold with a $3.00 price target. To see the full list of analyst forecasts on MEDIROM Healthcare Technologies stock, see the MRM Stock Forecast page.
Spark’s Take on MRM Stock
According to Spark, TipRanks’ AI Analyst, MRM is a Neutral.
The overall stock score is driven primarily by strong technical analysis indicators, suggesting positive market momentum. However, financial performance concerns, particularly related to profitability and cash flow, weigh down the score. Valuation is reasonable, but the lack of a dividend yield is a minor drawback.
To see Spark’s full report on MRM stock, click here.
More about MEDIROM Healthcare Technologies
MEDIROM Healthcare Technologies Inc. is a holistic healthcare company based in Japan. The company operates in the salon industry, providing health and wellness services through its salons and a health guidance program using its Lav® app, which supports lifestyle improvements to prevent lifestyle-related diseases.
Average Trading Volume: 4,833,796
Technical Sentiment Signal: Hold
Current Market Cap: $19.28M
See more data about MRM stock on TipRanks’ Stock Analysis page.

